Viatris Inc. Common Stock
VTRSViatris Inc. (VTRS) is a global healthcare company formed through the merger of Mylan and Pfizer’s Upjohn unit. The company specializes in developing, manufacturing, and marketing a broad range of pharmaceuticals, including generic, branded, and biosimilar medicines, with a focus on improving access to affordable healthcare worldwide.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| June 17, 2026 | $0.12 | 2026-05-22 | 2026-05-22 |
| March 18, 2026 | $0.12 | 2026-03-09 | 2026-03-09 |
| December 15, 2025 | $0.12 | 2025-11-24 | 2025-11-24 |
| September 15, 2025 | $0.12 | 2025-08-22 | 2025-08-22 |
| June 16, 2025 | $0.12 | 2025-05-23 | 2025-05-23 |
Dividends Summary
- Consistent Payer: Viatris Inc. Common Stock has rewarded shareholders with 21 dividend payments over the past 5 years.
- Total Returned Value: Investors who held VTRS shares during this period received a total of $2.49 per share in dividend income.
- Latest Payout: The most recent dividend of $0.12/share was paid 31 days ago, on June 17, 2026.
- Yield & Schedule: VTRS currently pays dividends quarterly with an annual yield of 2.78%.
- Dividend Growth: Since 2021, the dividend payout has grown by 9.1%, from $0.11 to $0.12.
- Dividend Reliability: VTRS has maintained or increased its dividend for 21 consecutive payments.
Company News
Novartis and Teva represent different pharmaceutical strategies: Novartis is a stable innovator with high margins and strong cash flow, while Teva is executing a turnaround from generics to biosimilars with improving profitability but higher debt. Despite Novartis's superior financial metrics, the article recommends Teva for long-term investors d...
Eli Lilly and Teva Pharmaceutical represent two different pharmaceutical strategies: Eli Lilly dominates the high-growth GLP-1 market with blockbuster drugs like Mounjaro and Zepbound, posting 44% revenue growth and trading at a 33x forward P/E. Teva operates in generics and biosimilars with lower valuations (16.4x forward P/E) but faces declinin...
The global tacrolimus market is projected to grow from USD 7.3 billion in 2025 to USD 12.7 billion by 2035 at a CAGR of 5.6%, driven by rising organ transplant procedures and increasing autoimmune disease prevalence. Injectable formulations and hospital settings dominate the market, with North America accounting for 40.4% of the market share. Key...
The presbyopia market is projected to grow at a CAGR of 4.9% from 2026-2036, driven by an aging global population and expanding treatment options. The market was valued at USD 11 billion in 2025 across seven major markets, with the US accounting for 50% of the market. Multiple emerging therapies and devices are expected to enter the market, inclu...
Opus Genetics will present three abstracts at the ASCRS Annual Meeting in April 2026, including full results from Phase 3 studies evaluating phentolamine ophthalmic solution for presbyopia and mesopic vision disturbances. The company's partner Viatris is sponsoring an educational symposium on presbyopia management. Opus Genetics is a clinical-sta...
